|Bid||35.65 x 1000|
|Ask||36.03 x 800|
|Day's range||35.63 - 37.20|
|52-week range||22.51 - 61.69|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||68.50|
London, UK – 21 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Danielle Schlosser PhD as Senior Vice-President, Clinical Innovation. Dr Schlosser will lead COMPASS’s Therapy Research and Training team, bringing her clinical experience in behavioural health and experience in digital health innovation. Danielle Schlosser joins COMPASS from
Legislation is starting to open up the industry but investors who are hoping to cash in on its growth opportunities could be waiting a very long time.
More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges.